A new clinical trial explored whether raising cellular NAD⁺ levels with high-dose nicotinamide riboside could influence lingering neurological and physical symptoms in long-COVID. Millions of people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback